NEW YORK, Oct. 26, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the Company has received approval to begin trading its common stock on the NASDAQ Capital Market. Anavex’s common stock will begin to trade on NASDAQ under the symbol “AVXL” at the opening of market hours on October 28, 2015.
“This is a significant milestone for Anavex. As we become a NASDAQ-listed company, our team is now able to communicate our progress with a broader audience, raise the visibility of Anavex's capabilities, as well as generate more value for our shareholders,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The NASDAQ uplisting also comes at an important time in our growth as full PART A and preliminary PART B Phase 2a clinical trial data will be presented at the CTAD conference on November 7, 2015.”
Before trading on NASDAQ commences on October 28, 2015, Anavex’s common stock will continue to trade on the OTCQX under the symbol “AVXLD.”
About Anavex™Life Sciences Corp.
Anavex Life Sciences Corp. (AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. Initial positive data was presented at AAIC 2015 and full PART A and preliminary PART B Phase 2a clinical trial data will be presented at CTAD in November 2015. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties indicating its potential to treat additional CNS disorders. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information Anavex™Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: email@example.com Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: firstname.lastname@example.org www.anavex.com
Source:Anavex Life Sciences Corp.